Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: Strong Long who wrote (1884)	4/26/2016 4:33:05 PM
From: mokelumne river	Read Replies (1) \| Respond to of 2026

SL, it is hard to argue with the fact that launches and rights did not move the pps. And regardless of future scenarios, I do not envision the type of run up that other biotechs have had in the past, even with very good news. I do think that the market is driven by US investors who are US centric. US investors (including many of us) saw the Abbott/Canada debacle unfold with agonizing drama. And US investors were right to be cautious about EU launches since the pace of Vitaros catching on there has been snail-like, especially with no advertising anywhere. At this point, I am fine with hunkering down for a year, as long as the company can remain a going concern. I do not think the latter is a high bar considering that the debt is really pretty small at $9M and company intends to cut way back (60%) in terms of operating expenses. Even the specter of delisting is not a huge deal, although I am firmly in MI's camp that delisting is not going to happen, particularly in light of the timing of events that I outlined in my last post. Thanks for the conversation. James